Search
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt will compare pixantrone efficacy to that of gemcitabine. [2] … It is currently being tested in Phase III trials. [2] Although pixantrone has not yet received FDA approval in the United States, it has been granted conditional marketing approval by the European Union
Cyclopentamine
go.drugbank.com/drugs/DB08999ApprovedWithdrawnCyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia.
Sumatriptan
go.drugbank.com/drugs/DB00669ApprovedInvestigational[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.
Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnEtoperidone is an atypical antidepressant introduced in Europe in 1977.
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalUse (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients with Alagille syndrome:[L43547] it was granted marketing authorization in Europe
Leflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Nirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigationalL46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European
Gestrinone
go.drugbank.com/drugs/DB11619ApprovedGestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and
Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigationalPirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneum...
Tecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022.